September 19, 2025
EADV 2025: Guttman-Yassky presented data from the phase 3 ROCKET-IGNITE trial and highlights its importance in the context of the global ROCKET development program.
September 19, 2025
Your daily dose of the clinical news you may have missed.
September 19, 2025
EADV 2025: Phase 3 ROCKET-SHUTTLE results showed the T-cell rebalancing therapy significantly improved AD signs and symptoms in treatment-experienced adults.
September 18, 2025
Ada Stewart, MD, reviews current guidelines, addresses patient hesitancy, and explains how HPV self-collection tests may expand screening options in primary care.
September 18, 2025
The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.
September 18, 2025
EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.
September 18, 2025
The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.
September 18, 2025
In children aged 10 to
September 18, 2025
Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.
September 17, 2025
Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.